Investor Value
Transpire Bio: A unique investor opportunity
Significant revenue growth opportunities without the typical risk profile of other biopharmaceutical companies.
Transpire Bio: A unique investor opportunity
Significant revenue growth opportunities without the typical risk profile of other biopharmaceutical companies.
Typical biopharmaceutical startup model
In a typical biopharmaceutical startup, investment risk is amplified by the binary nature of the clinical asset’s success:
Transpire Bio’s unique value proposition
Our inhalation technology platform approach, which offers multiple strategic options and revenue sources, helps mitigate this traditional biopharmaceutical investment risk:
Significantly lower risk of R&D/commercial failure
Sizable upside opportunity:
Licensing cash flow and innovation portfolio
Downside risk mitigated:
OpEx covered by current partnerships and investments
Significant traction advancing and de-risking development
We have made significant progress building organizational capabilities and advancing our innovation, increasing investor value and decreasing investor risk:
Fully developed inhalation technologies
- Clinical-stage delivery platforms & formulation technology
- Multiple assets advancing in development/clinicals
- Robust IP portfolio
Robust core capabilities built
- Leadership team with deep inhalation expertise
- Multiple partnerships established or in process
- Investment in specialized, high-capacity manufacturing
- Currently generating eight-figure revenues
Multiple strategic options
- Customizable platform enables flexibility in compounds and clinical applications
- Unrivaled latitude in partnering options
- Ability to execute across the biopharmaceutical value stream (mid-stage or late-stage exit)
Multiple revenue streams
- Big pharma co-development partnerships
- Out-licensing deals for complex generics
- Advancing an innovative biopharmaceutical portfolio
Significant revenue
growth potential
Reduced risk profile compared to other typical biopharma investments
1. Dowden H., Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov. 2019;18:495–496. doi: 10.1038/d41573-019-00074-z.
